Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Alzamend Neuro, Inc. Common Stock

ALZN

Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's disease. The Company has two therapeutic drug candidates, AL001 and ALZN002. Its pipeline consists of AL001, a patented ionic cocrystal technology delivering lithium through a therapeutic combination of lithium, proline and salicylate; and ALZN002, a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's disease.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $1.12 – $1.19
Volume 17,301
Market cap $6M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$5.69M
Price / earnings
—
Price / book
0.98×
Price / sales
—
EV / sales
—
EV / EBITDA
0.21×

Profitability

Earnings per share
-$1.89
Return on assets
-106.49%
Return on equity
-156.77%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
3.01×
Quick ratio
3.01×
Cash ratio
2.77×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$6.84M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ALZN, quarterly periods
Line itemQ1 FY2027 Jul 31, 2026Q4 FY2026 Apr 30, 2026Q3 FY2026 Jan 31, 2026Q2 FY2026 Oct 31, 2025Q1 FY2026 Jul 31, 2025Q4 FY2025 Apr 30, 2025Q3 FY2025 Jan 31, 2025Q2 FY2025 Oct 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$1.94M$2.44M$919.03K$821.83K$959.33K$688.78K$590.3K$1.05M
Research and development$1.09M$434.01K$1.28M$176.28K$1.74M$450.16K$447.11K$311.09K
Total operating expenses$3.03M$2.87M$2.2M$998.11K$2.7M$1.14M$1.04M$1.36M
Operating income-$3.03M-$2.87M-$2.2M-$998.11K-$2.7M-$1.14M-$1.04M-$1.36M
Interest expense-$2.01K-$150-$1.34K-$2.65K-$2.48K-$509-$2.02K-$3.5K
Income before taxes-$3.03M-$2.87M-$2.2M-$1M-$2.7M-$1.14M-$1.04M-$1.36M
Income taxes$0$0$0$0$0$0$0$0
Net income-$3.03M-$2.87M-$2.2M-$1M-$2.7M-$1.14M-$1.04M-$1.36M
Net income attributable to common shareholders-$3.03M-$2.87M-$2.2M-$1M-$2.7M-$1.64M-$1.07M-$1.42M
EBITDA-$3M-$2.84M-$2.17M-$970.42K-$2.67M-$1.13M-$1.02M-$1.36M
Basic earnings per share-$0.68-$0.71-$0.58-$0.30-$1.28-$2.30-$1.75-$3.60
Diluted earnings per share-$0.68-$0.71-$0.58-$0.30-$1.28-$2.30-$1.75-$3.60

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Alzamend Neuro (ALZN) Upgraded to Buy: What Does It Mean for the Stock?

Alzamend Neuro has been upgraded to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The upgrade reflects improving business fundamentals, with analysts raising consensus estimates by 59.6% over the past three months. The stock is positioned in the top 20% of Zacks-covered stocks and may experience near-term price appreciation.

Benzinga

Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying

The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Aldeyra Therapeutics The Trade: Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) 10% owner Joseph Edelman acquired a total of 504,272 shares an average price of $3.84. To acquire these shares, it cost around $1.93 million. What’s Happening: On April ...

Benzinga

Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying

The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Alzamend Neuro The Trade: Alzamend Neuro, Inc. (NASDAQ: ALZN) Director Milton C Ault III acquired a total of 2,000 shares an average price of $1.06. To acquire these shares, it cost around $2,127.. What’s Happening: On Dec. 11, 2023, Alzamend Neuro received a "Study May Proceed" letter from the FDA for the initiation of study AL001-PTSD01, a Phase 2A study of AL001 for post-traumatic stress disorder (PTSD). What ...

Benzinga

Alzamend Neuro And 3 Other Stocks Under $3 Insiders Are Buying

$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying The Dow Jones index closed lower by over 150 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. Fortress Biotech The Trade: Fortress Biotech, Inc. (NASDAQ: FBIO) President, CEO and Chairman MD Lindsay Rosenwald acquired a total of 50,000 shares an average price of $2.38. To acquire these shares, it cost around $118,770. What’s Happening: Fortress Biotech recently announced pricing of an $11 million registered direct offering priced at-the-market under Nasdaq rules. What Fortress Biotech Does: Fortress Biotech Inc is a ...

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
May 12, 20251-for-9reverse split
Jul 16, 20241-for-10reverse split
Oct 31, 20231-for-15reverse split